KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Other Non-Current Liabilities (2017 - 2025)

Historic Other Non-Current Liabilities for Neogenomics (NEO) over the last 10 years, with Q3 2025 value amounting to $12.0 million.

  • Neogenomics' Other Non-Current Liabilities rose 328.56% to $12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.0 million, marking a year-over-year increase of 328.56%. This contributed to the annual value of $11.8 million for FY2024, which is 968.24% down from last year.
  • Neogenomics' Other Non-Current Liabilities amounted to $12.0 million in Q3 2025, which was up 328.56% from $12.1 million recorded in Q2 2025.
  • Over the past 5 years, Neogenomics' Other Non-Current Liabilities peaked at $14.4 million during Q3 2021, and registered a low of $3.7 million during Q1 2021.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $13.0 million (2023), whereas its average is $12.0 million.
  • Per our database at Business Quant, Neogenomics' Other Non-Current Liabilities plummeted by 1246.75% in 2021 and then surged by 28146.75% in 2022.
  • Quarter analysis of 5 years shows Neogenomics' Other Non-Current Liabilities stood at $14.0 million in 2021, then fell by 6.9% to $13.1 million in 2022, then decreased by 0.16% to $13.0 million in 2023, then dropped by 9.68% to $11.8 million in 2024, then grew by 1.74% to $12.0 million in 2025.
  • Its last three reported values are $12.0 million in Q3 2025, $12.1 million for Q2 2025, and $11.9 million during Q1 2025.